Genesys Spine's SIros System Clinically Proven to Reduce SI Joint Pain

AUSTIN, TX – February 06, 2026 – For the millions suffering from chronic lower back pain stemming from the sacroiliac (SI) joint, a new study offers validated hope. Genesys Spine, an Austin-based medical device company, today released compelling results from a prospective multicenter clinical study of its SIros® Lateral Sacroiliac Joint Fusion System. The findings, published in the peer-reviewed Pain Physician Journal, demonstrate that the minimally invasive implant significantly reduces pain, improves physical function, and cuts opioid use in half for patients with debilitating SI joint dysfunction.

The results provide robust clinical validation for the 3D-printed titanium implant, strengthening its position as a leading treatment in a rapidly growing medical technology market.

The Clinical Evidence: A Closer Look at the Numbers

The prospective study was designed to rigorously evaluate the safety and effectiveness of the SIros system. The data revealed a dramatic improvement in patient-reported outcomes over six months. Patients in the study experienced a 38% reduction in pain, with the average Numerical Rating Scale (NRS) score dropping from a severe 6.8 at baseline to a more manageable 4.2.

"The study confirms that the SIros system delivers pain relief and functional outcomes comparable to other titanium-based implants, while also achieving excellent safety, optimal operative parameters, and low fluoroscopic exposure," stated Dr. Douglas P. Beall, an esteemed interventional spine specialist and the study's Principal Investigator.

Functional improvement was equally significant. The Oswestry Disability Index (ODI), a standard measure of how back pain impacts daily life, improved from a baseline average of 50.3% to 34.9%. This represents a meaningful clinical shift for patients, moving them from a state of "severe disability" to "moderate disability," often meaning the difference between being housebound and regaining an active life.

Radiographic assessments confirmed the device's efficacy in promoting fusion. At the six-month mark, 96% of patients showed evidence of bone apposition to the implants, and an impressive 72% demonstrated bone bridging across the SI joint—the definitive goal of the fusion procedure. Critically, the study reported zero instances of implant failure, device migration, or procedure-related serious adverse events, underscoring the system's strong safety profile. Perhaps one of the most impactful findings was a nearly 50% decline in opioid use among the patient cohort, a significant achievement amid the ongoing public health focus on reducing reliance on pain medication.

A Growing Market Hungry for Solutions

These clinical results arrive at a pivotal moment for the sacroiliac joint fusion market. Long underdiagnosed, SI joint dysfunction is now recognized as the primary pain generator in 15% to 30% of patients with chronic lower back pain. This growing awareness has fueled a surge in demand for effective treatments.

The global SI joint fusion market, valued at over $720 million in 2023, is projected to expand at a compound annual growth rate of nearly 20%, potentially reaching $2.5 billion by 2030. Genesys Spine's positive data positions the company to compete more effectively against established players like SI-BONE, Medtronic, and Globus Medical.

"The prospective study further validates SIros as a key solution for SI joint fusion," commented Meredith Gavlick, Chief Strategy Officer, SI Fusion at Genesys Spine. "Demonstrating stabilization with minimal radiation exposure and a minimally invasive approach represents a major advancement for patient outcomes and recovery."

The trend towards minimally invasive surgery (MIS) is a key driver of this market growth. Surgeons and patients alike favor MIS approaches for their proven benefits, including smaller incisions, less blood loss, reduced post-operative pain, and significantly faster recovery times compared to traditional open surgery. Genesys Spine's SIros system, which received FDA 510(k) clearance in late 2025, is designed specifically for this minimally invasive approach.

The Patient Perspective: Beyond the Statistics

While the statistical improvements are impressive, their true significance lies in the profound impact on patients' quality of life. For individuals whose lives have been constrained by chronic pain, a procedure that allows them to walk, work, and engage in family activities without constant agony is transformative. The reduction in the ODI score from "severe" to "moderate" disability is not just a number; it represents a return to independence.

An independent orthopedic surgeon not involved with the study noted that effective, evidence-backed treatments for SI joint dysfunction are desperately needed. "For years, these patients were often misdiagnosed or told their pain was 'in their head.' Having a minimally invasive option with data showing it not only reduces pain but helps patients get off opioids is a massive win for both patients and the clinicians who treat them," he explained.

The ability of the SIros system to facilitate such a significant reduction in opioid consumption is a particularly vital aspect of its success. By addressing the underlying structural cause of the pain, the fusion procedure offers a long-term solution rather than a temporary palliative, directly combating the cycle of chronic pain and opioid dependence.

Innovation Driving a Paradigm Shift in Spinal Care

The success of the SIros study is emblematic of a broader paradigm shift in spinal medicine towards safer, more effective, and less invasive interventions. The system's implants are manufactured using advanced 3D-printing technology, creating a porous titanium structure that encourages the patient's own bone to grow into and through the device, achieving a durable biological fusion.

This technological sophistication, combined with the minimally invasive surgical technique, addresses key demands of modern healthcare: efficiency, safety, and long-term value. Procedures that reduce operative time, minimize radiation exposure for both patient and staff, and shorten hospital stays are increasingly favored by healthcare systems. The favorable reimbursement landscape for MIS SI joint fusion, with coverage from most major private insurers and Medicare, further ensures patient access to these advanced treatments.

By delivering robust, peer-reviewed clinical evidence of its safety and efficacy, Genesys Spine has not only validated its own technology but has also contributed to the growing body of evidence supporting MIS SI joint fusion as a standard of care. This commitment to clinical rigor provides surgeons with the confidence to adopt new technologies and assures patients that they are receiving a treatment backed by science, marking a significant step forward in resolving a common and debilitating source of chronic pain.